Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.

[1]  M. Suarez‐Almazor,et al.  Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. , 2012, JAMA.

[2]  M. Hochberg,et al.  Malignancy validation in a United States registry of rheumatoid arthritis patients , 2012, BMC Musculoskeletal Disorders.

[3]  V. Lemmens,et al.  Record linkage for pharmacoepidemiological studies in cancer patients , 2012, Pharmacoepidemiology and drug safety.

[4]  J. Kremer,et al.  Integrated safety in tocilizumab clinical trials , 2011, Arthritis research & therapy.

[5]  A. Zeringue,et al.  Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. , 2011, Rheumatology.

[6]  J. Pope,et al.  Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. , 2011, Arthritis and rheumatism.

[7]  D. Symmons,et al.  Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta‐analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data , 2011, Pharmacoepidemiology and drug safety.

[8]  W. Dixon,et al.  SPECIAL ARTICLE: DRUG SAFETY IN THE RHEUMATIC DISEASES Influence of Anti–Tumor Necrosis Factor Therapy on Cancer Incidence in Patients With Rheumatoid Arthritis Who Have Had a Prior Malignancy: Results From the British Society for Rheumatology , 2022 .

[9]  L. Jacobsson,et al.  Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? , 2009, Arthritis and rheumatism.

[10]  M. Hochberg,et al.  Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment , 2008, Annals of the rheumatic diseases.

[11]  E. Matteson,et al.  Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials , 2008, Annals of the rheumatic diseases.

[12]  T. Einarson,et al.  The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events , 2008, Annals of the rheumatic diseases.

[13]  L. Jacobsson,et al.  Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register , 2008, Annals of the rheumatic diseases.

[14]  S. Suissa,et al.  Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. , 2008, Archives of internal medicine.

[15]  S. Suissa,et al.  Lung cancer after exposure to disease modifying anti-rheumatic drugs. , 2008, Lung cancer.

[16]  Michael H Weisman,et al.  New therapies for treatment of rheumatoid arthritis , 2007, The Lancet.

[17]  F. Wolfe,et al.  Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. , 2007, Arthritis and rheumatism.

[18]  S. Schneeweiss,et al.  Developments in Post‐marketing Comparative Effectiveness Research , 2007, Clinical pharmacology and therapeutics.

[19]  F. Wolfe,et al.  The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. , 2007, Arthritis and rheumatism.

[20]  J. Avorn,et al.  Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[21]  Peter C Austin,et al.  A comparison of propensity score methods: a case‐study estimating the effectiveness of post‐AMI statin use , 2006, Statistics in medicine.

[22]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[23]  Til Stürmer,et al.  Indications for propensity scores and review of their use in pharmacoepidemiology. , 2006, Basic & clinical pharmacology & toxicology.

[24]  F. Wolfe,et al.  Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. , 2005, The Journal of rheumatology.

[25]  J. Smolen,et al.  The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. , 2005, Clinical and experimental rheumatology.

[26]  J. Kremer,et al.  The CORRONA database. , 2006, Autoimmunity reviews.

[27]  M. Dougados,et al.  Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[28]  L. Jacobsson,et al.  Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists , 2005, Annals of the rheumatic diseases.

[29]  H. Olsson,et al.  Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas , 2005, Annals of the rheumatic diseases.

[30]  X. Mariette,et al.  Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. , 2002, Blood.

[31]  F. Wolfe,et al.  Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation. , 2001, The Journal of rheumatology.

[32]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[33]  Lars Klareskog,et al.  Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study , 1998, BMJ.

[34]  J. Kremer.  Is methotrexate oncogenic in patientswith rheumatoid arthritis , 1997 .

[35]  Yunus Mb,et al.  Non-Hodgkin's lymphoma in patients with rheumatoid arthritis treated with low dose methotrexate , 1996 .

[36]  S. Kingsmore,et al.  Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. , 1992, The Journal of rheumatology.

[37]  B. Hazleman.  Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens. , 1985, The American journal of medicine.

[38]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[39]  W. Bleyer,et al.  Methotrexate: clinical pharmacology, current status and therapeutic guidelines. , 1977, Cancer treatment reviews.

[40]  J. Avorn,et al.  Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[41]  M. Pillinger.  Treatment of Rheumatoid Arthritis With the Selective Costimulation Modulator Abatacept: Twelve-Month Results of a Phase IIb, Double-blind, Randomized, Placebocontrolled Trial , 2006 .

[42]  J. Kremer.  Is methotrexate oncogenic in patients with rheumatoid arthritis? , 1997, Seminars in arthritis and rheumatism.

[43]  M. Yunus,et al.  Non-Hodgkin's lymphoma in patients with rheumatoid arthritis treated with low dose methotrexate. , 1996, The Journal of rheumatology.

[44]  T. Hakulinen,et al.  Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. , 1978, Journal of chronic diseases.